Connect your AI

Lifecore Biomedical, Inc. LFCR Price / book

Price / book at other companies

Baxter InternationalBAX

1.4×-1.0×

Thermo Fisher ScientificTMO

3.5×-0.3×

ADMA BiologicsADMA

5.5×-7.1×

Medpace Holdings, Inc.MEDP

22.8×+7.1×

Biodesix, Inc.BDSX

15.7×+7.4×

ClearPoint NeuroCLPT

14.3×-2.1×

Other financials

Income statement

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Balance sheet

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Cash flow

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Valuation

Market cap$196.92M-37.3%

Enterprise value$333.06M+6.3%

P/S1.6×+0.5×

Profitability

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Returns & leverage

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Where this comes from

Calculated from Lifecore Biomedical, Inc.’s reported figures.

market cap/total stockholders equity=194×

Based on the most recent quarter.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Lifecore Biomedical, Inc.'s price / book?: Lifecore Biomedical, Inc. (LFCR) reported price / book of 194× in Q1 2025.
How has Lifecore Biomedical, Inc.'s price / book changed year-over-year?: Lifecore Biomedical, Inc.'s price / book increased by 1139.6% year-over-year, from 15.7× to 194×.
What is the long-term trend for Lifecore Biomedical, Inc.'s price / book?: Over 3 years (2021 to 2025), Lifecore Biomedical, Inc.'s price / book has grown at a 380.7% compound annual growth rate (CAGR), from 1.7× to 194×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.